Dr. Jon Wilensky, MD MBA, is a Board Certified Plastic Surgeon and Diplomate of the American Board of Plastic Surgery, based in the San Diego and the Central Valley regions of California. With over 19 years of experience, he specializes in Aesthetic Surgery of the breast and body, including tummy tucks, breast augmentation, breast lift, liposuction, and fat transfer. Dr. Wilensky is also a prolific researcher and writer, having published numerous papers, particularly on traumatic wounds and general Plastic & Reconstructive Surgery.
A native of New York City, Dr. Wilensky was born to public servants, an elementary school teacher and an NYPD police officer. He attended The Stuyvesant High School, the premier public math and science high school, which required a rigorous 2-hour commute each way from Staten Island to Manhattan. At 17, he was one of just nine high school seniors nationwide invited to attend both undergraduate and medical school at The University of Michigan as part of the prestigious 7-Year Integrated BS-MD dual degree program. By 24, he completed his MD degree at The University of Michigan Medical School and matched into the highly competitive Integrated Plastic Surgery residency program at the University of Michigan Health System, completing this rigorous 6-year post-MD training in 2006. He achieved Board Certification from the American Board of Plastic Surgery in November 2007, having just turned 32 the month prior, becoming the youngest Plastic Surgeon to ever be Certified by the Board.
Dr. Wilensky is deeply invested in the emerging fields of implantable biotechnology and cellular therapeutics. He has served as Lead Surgeon in multiple clinical trials, including studies on implantable sensors and cell therapy, and has consulted for numerous early- and mid-stage companies. He recently served as the Head of Surgery for ViaCyte, Inc., which was acquired by VERTEX Pharmaceuticals to advance curative programs for Type 1 Diabetes. He currently serves as a Surgical & Technical Consultant to both Encellin and Novo Nordisk/Aspect Biosystems, helping to guide their implantable cell therapy and implantable bioprinted tissue therapy programs, respectively.